News - EGFR exon 2-7 deletion + EGFR amplification

4years

Glioblastomas harboring gene fusions detected by next-generation sequencing. (PubMed, Brain Tumor Pathol)

Additionally, we described two novel cases of CCDC6-RET fusion in glioma. Collectively, our findings indicate that targetable gene fusions are associated with aggressive biological behavior and can aid the clinical treatment strategy for glioma patients.

4 years ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • TERT (Telomerase Reverse Transcriptase) • CCDC6 (Coiled-Coil Domain Containing 6) • ATRX (ATRX Chromatin Remodeler) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • NTRK (Neurotrophic receptor tyrosine kinase)

TP53 mutation • RET fusion • EGFR amplification • PTEN mutation • CCDC6-RET fusion • ATRX mutation • EGFR exon 2-7 deletion + EGFR amplification • EGFR mutation + PTEN mutation • MET fusion

4years

Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer. (PubMed, Clin Cancer Res)

Ramucirumab plus osimertinib demonstrated encouraging safety and antitumor activity in T790M-positive EGFR-mutant NSCLC.

4 years ago

Clinical • P1 data • Journal • Combination therapy

EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR amplification • EGFR C797S • EGFR L858R + EGFR T790M • EGFR C797S + EGFR T790M + EGFR L858R • EGFR C797S + EGFR T790M + EGFR exon 19 deletion • EGFR positive • MET amplification + EGFR mutation • EGFR T790M + EGFR C797S • EGFR exon 2-7 deletion + EGFR amplification • EGFR mutation + EGFR T790M • EGFR exon 19 deletion + MET amplification • EGFR mutation + EGFR T790M + EGFR C797S • EGFR T790M + exon 19 deletion

Tagrisso (osimertinib)

over4years

[VIRTUAL] Identification of targetable alterations using NGS-based liquid biopsy in NSCLC patients (ESMO 2020)

Funding: This study was supported by CB16/12/00350 and P118/00226 from ISCIII and Asociación de Mujeres de Apoyo al Cáncer de Mama (AMACMA). AM is recipient of PhD scholarship from Asociación Española Contra el Cáncer (AECC) Valencia Scientific Foundation.

over 4 years ago

Clinical • Liquid biopsy • Next-generation sequencing

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • CDK4 (Cyclin-dependent kinase 4)

TP53 mutation • BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • HER-2 amplification • BRAF V600 • EGFR L858R • EGFR T790M • KRAS G12V • EGFR L858R + EGFR T790M • KRAS G12 • EGFR mutation + BRAF V600E • EGFR mutation + KRAS mutation • BRAF mutation + MET amplification • EGFR T790M + KRAS mutation • EGFR exon 2-7 deletion + EGFR amplification • EGFR mutation + EGFR T790M

Oncomine™ Pan-Cancer Cell-Free Assay